Latest & greatest articles for estradiol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on estradiol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on estradiol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for estradiol

21. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale (...) replacement therapy (HRT), which typically involves administration of estrogen and progesterone via pills, skin patches, or gels. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Estradiols; Postmenopause Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Health Technology Assessment (HTA) Database.2012

22. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale (...) by use of hormone replacement therapy (HRT), which typically involves administration of estrogen and progesterone via pills, skin patches, or gels. Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Drug Implants; Estradiol; Estrogen Replacement Therapy; Females; Menopause Language Published English Country

Health Technology Assessment (HTA) Database.2011

23. Ioa - nomegestrol acetate / estradiol

Ioa - nomegestrol acetate / estradiol 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report Ioa nomegestrol/estradiol Procedure No.: EMEA/H/C/002068 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorisedIoa CHMP assessment (...) Pharmaceutical Ingredient AST Aspartate Aminotransferase AUC Area Under the Curve BE Bioequivalence BMI Body Mass Index CI Confidence Interval Cmax Maximum Plasma Concentration Cmax,ss,cor Maximum Plasma Concentration at steady state, corrected for the residual concentration of previous doses CBG Corticosteroid Binding Globulin COC Combined Oral Contraceptive CRP C-reactive protein CTR Clinical trial report DRSP-EE Drospirenone - Ethinyl Estradiol E1 Estrone E1S Estrone sulphate E2 17 ß-estradiol FD Follicle

European Medicines Agency - EPARs2011

24. Zoely - nomegestrol / estradiol

Zoely - nomegestrol / estradiol 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report Zoely International Non proprietary Name: nomegestrol/estradiol Procedure No. EMEA/H/C/001213 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Table of contents 1. Background (...) exception contain 17- alpha-ethinylestradiol (EE) and some first generation combined hormonal contraceptives contain mestranol. 19-nor-testosteron derivatives have, besides their gestagenic effects, mild to moderate androgenic effects and might have negative impact on the lipid metabolism. They can also cause intrahepatic cholestasis. Nomegestrol Acetate (NOMAC) is a highly selective progestin derived from the naturally occurring steroid hormone, progesterone. The 17 ß-estradiol (E2) compound

European Medicines Agency - EPARs2011

25. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale

Health Technology Assessment (HTA) Database.2010

26. Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets

Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets Drug Approval Package: Norethindrone and Ethinyl estradiol NDA #022573 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets Company: Warner Chilcott, LLC Application No.: 022573 Approval Date: 12/22/2010 Persons with disabilities having problems accessing the PDF files

FDA - Drug Approval Package2010

27. Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets)

Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Drug Approval Package: Safyral (drospirenone/ethinyl estradiol) NDA #022574 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022574 Approval Date: 12/16/2010 Persons

FDA - Drug Approval Package2010

28. Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets)

Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets) Drug Approval Package: Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate) NDA #022501 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate

FDA - Drug Approval Package2010

29. Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium)

Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) Drug Approval Package: Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) NDA #022532 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) tablets Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022532 Approval Date: 09/24/2010 Persons

FDA - Drug Approval Package2010

30. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study

Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study 19737330 2009 10 07 2009 10 28 2016 10 19 1532-5415 57 10 2009 Oct Journal of the American Geriatrics Society J Am Geriatr Soc Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. 1810-5 10.1111/j.1532-5415.2009.02464.x To investigate the relationship between total estradiol (E2) levels and 9-year mortality in older (...) HHS United States N01-AG-916413 AG NIA NIH HHS United States Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't 2009 09 08 United States J Am Geriatr Soc 7503062 0002-8614 4TI98Z838E Estradiol IM Endocr Rev. 2007 Aug;28(5):521-74 17640948 Nutr Cancer. 2006;56(2):253-9 17474873 Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2042-7 17905944 Cancer Res. 2008 Jan 1;68(1):329-37 18172327 JAMA. 2002 Aug 21;288(7):872-81 12186605

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

32. Circulating estradiol and mortality in men with systolic chronic heart failure.

Circulating estradiol and mortality in men with systolic chronic heart failure. CONTEXT: Androgen deficiency is common in men with chronic heart failure (HF) and is associated with increased morbidity and mortality. Estrogens are formed by the aromatization of androgens; therefore, abnormal estrogen metabolism would be anticipated in HF. OBJECTIVE: To examine the relationship between serum concentration of estradiol and mortality in men with chronic HF and reduced left ventricular ejection (...) fraction (LVEF). DESIGN, SETTING, AND PARTICIPANTS: A prospective observational study at 2 tertiary cardiology centers (Wroclaw and Zabrze, Poland) of 501 men (mean [SD] age, 58 [12] years) with chronic HF, LVEF of 28% (SD, 8%), and New York Heart Association [NYHA] classes 1, 2, 3, and 4 of 52, 231, 181, and 37, respectively, who were recruited between January 1, 2002, and May 31, 2006. Cohort was divided into quintiles of serum estradiol (quintile 1, < 12.90 pg/mL; quintile 2, 12.90-21.79 pg/mL

JAMA2009

34. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy 19104361 2008 12 23 2009 02 24 2013 11 21 0029-7844 113 1 2009 Jan Obstetrics and gynecology Obstet Gynecol Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. 65-73 10.1097/AOG.0b013e31818e8cd6 To estimate the risk for breast cancer in Finnish women using postmenopausal estradiol (E2)-progestogen therapy. All Finnish women over 50 years using E2-progestogen therapy for at least 6 months (...) elevation may not be uniform for all progestogens. II. Lyytinen Heli H Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. Pukkala Eero E Ylikorkala Olavi O eng Comment Journal Article Research Support, Non-U.S. Gov't United States Obstet Gynecol 0401101 0029-7844 0 Progestins 4TI98Z838E Estradiol AIM IM Obstet Gynecol. 2009 Jan;113(1):74-80 19104362 Administration, Cutaneous Administration, Oral Aged Aged, 80 and over Breast Neoplasms chemically induced

EvidenceUpdates2009

35. Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy

Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy | Therapeutics Initiative Independent Healthcare Evidence > > Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy This is the summary of a systematic review assessing the comparative safety and efficacy of Seasonale (ethinyl estradiol 30 μg, levonorgestrel 150 μg, extended 91-day (...) cycle), in the prevention of pregnancy in sexually active women of reproductive age. Drug This oral contraceptive (OC) combines an estrogen, ethinyl estradiol (EE) 30 μg, and a progestin, levonorgestrel (LNG)150 μg, commonly contained in other OCs in Canada. Duration of active treatment for this product is 84 days, followed by 7 days of placebo. It is the only product available in Canada that is specifically formulated for extended-cycle use. The aim of this formulation, in addition to pregnancy

Therapeutics Letter2009

36. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 19690310 2009 08 19 2009 08 25 2017 02 20 1538-3598 302 7 2009 Aug 19 JAMA JAMA Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. 774-80 10.1001/jama.2009.1204 Estrogen deprivation therapy with aromatase inhibitors has been (...) hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy. To determine whether 6 mg of estradiol (daily) is a viable therapy for postmenopausal women with advanced aromatase inhibitor-resistant hormone receptor-positive breast cancer. A phase 2 randomized trial of 6 mg vs 30 mg of oral estradiol used daily (April 2004-February 2008 [enrollment closed]). Eligible patients (66 randomized) had metastatic breast cancer treated with an aromatase

JAMA2009 Full Text: Link to full Text with Trip Pro

37. The Effect of Oral 17?-estradiol on Various Cardiovascular Atherosclerotic Indices in Postmenopausal Women: Does Chemical Structure Make a Difference?

The Effect of Oral 17?-estradiol on Various Cardiovascular Atherosclerotic Indices in Postmenopausal Women: Does Chemical Structure Make a Difference? "The Effect of Oral 17β-estradiol on Various Cardiovascular Atheroscler" by Britany C. Rowan < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Anya Hill, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS, PA-C Rights (...) trials have been conducted recently to examine the effect of oral 17β-estradiol as opposed to conjugated equine estrogen, on the progression of atherosclerotic disease in postmenopausal women. Objective: To determine whether oral 17β-estradiol with or without sequentially administered progestogen therapy has an effect on the progression and/or prevention of cardiovascular disease in postmenopausal women. Study Design: Systematic review of the available medical literature. Methods: An exhaustive

Pacific University EBM Capstone Project2009

38. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial

Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial 18515518 2008 06 02 2008 07 24 2014 07 30 0029-7844 111 6 2008 Jun Obstetrics and gynecology Obstet Gynecol Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. 1343-51 10.1097/AOG.0b013e318175d162 To investigate the safety and efficacy of a transdermal estradiol (E2) spray in women with postmenopausal vasomotor symptoms. A randomized, double-blind, placebo-controlled, multicenter (...) 0401101 0029-7844 4TI98Z838E Estradiol AIM IM Nat Clin Pract Endocrinol Metab. 2009 Jan;5(1):18-9 19079270 Administration, Cutaneous Double-Blind Method Estradiol administration & dosage adverse effects Female Hot Flashes drug therapy Humans Middle Aged Postmenopause Treatment Outcome 2008 6 3 9 0 2008 7 25 9 0 2008 6 3 9 0 ppublish 18515518 111/6/1343 10.1097/AOG.0b013e318175d162

EvidenceUpdates2008

39. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women

The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women 18313446 2008 03 03 2008 04 08 2013 11 21 1097-6868 198 3 2008 Mar American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. 265.e1-7 10.1016/j.ajog.2007.09.039 This study was undertaken to examine the effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. Analysis (...) of data from a multicenter, randomized, double-blind, placebo-controlled trial of a 0.014 mg/day transdermal estradiol patch in 417 women aged 60 to 80 years. Sexual function was assessed by self-administered questionnaires at baseline and 4, 12, and 24 months. A linear effects model was used to assess treatment effects using data from all on-study assessments. Women randomly assigned to estradiol had a 4.3 point greater improvement in the vaginal pain/dryness domain relative to placebo (95% CI = 0.3

EvidenceUpdates2008

40. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis

The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG (...) /intracytoplasmic sperm injection, there is a need for a large, well-designed, multicentre randomised controlled trial to investigate the optimal dose and route of administration. Funding Not reported. Bibliographic details Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertility and Sterility 2008; 90(6): 2116-2125 PubMedID DOI Original Paper URL Indexing Status Subject indexing

DARE.2008